Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS) have approved national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for people ages two and older with cystic fibrosis (CF) who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with KALYDECO® (ivacaftor) for eligible patients in Spain living with cystic fibrosis (CF).
As a widely recognized biotech hub, Boston is undoubtedly one of the best places to start a new company at the frontier of biology and engineering. With a dense network of incubators, venture capitalists and talent, seasoned company founders can have their pick of partners and models launching their latest startups.
If the folks at Vertex are rolling their eyes at a new social media campaign from Association of the British Pharmaceutical Industry (ABPI), it would certainly be understandable.
A group of UK parents have been driven to take matters into their own hands to gain access to the cystic fibrosis treatment Orkambi, which is currently unavailable to most patients in the country.
A breakthrough on access to Vertex’s cystic fibrosis drug Orkambi in England looked to be round the corner earlier this year – but two more months of silence has prompted calls for an update from MPs and campaigners.
The UK’s health secretary Matt Hancock met Vertex’s chief executive Jeff Leiden in London yesterday with the aim of breaking the impasse over cystic fibrosis drug Orkambi.
AbbVie takes over cystic fibrosis drugs from Galapagos